Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Bayer : foundations bring tech pioneers, physicians and social entrepreneurs to the World Health Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
10/13/2017 | 10:05am CEST

Leverkusen, October 13, 2017- The World Health Summit will be held on October 15-17, 2017, in Berlin under the patronage of German Chancellor Angela Merkel, French President Emmanuel Macron and European Commission President Jean-Claude Juncker. Key topics this year are health policy in the G7/G20, new vaccine research and development, digitalization and big data, health security, urban health, and Africa and the United Nations' sustainability goals. This year's speakers include seven government ministers from six countries, two Nobel laureates, and CEOs of businesses and NGOs - including Werner Baumann, Chairman of the Board of Management of Bayer AG.

The Bayer foundations have been supporting the World Heath Summit since 2014 with financial sponsorship in the form of participant stipends in the Young Physician Leaders (YPL) Program and with subject-matter expertise in dialog events. YPL alumnus Dr. Kalana Maduwage's project is a particularly impressive success story. The physician, scientist, social entrepreneur and snake expert from Sri Lanka took part in the summit last year as a Bayer stipend recipient and garnered enthusiasm with a unique innovation. In his home country alone, around 80,000 farmers are bitten by snakes in their fields every year. The doctors there face a real dilemma: there is never enough antivenom available to treat all of the patients, but anyone receiving treatment too late has little chance of a successful recovery. Maduwage recognized this dilemma from his own work as a physician and is currently working on developing a fast enzyme-based test to determine the actual concentration of snake venom in a patient's blood. In the future, doctors will be able to administer the limited medication in a targeted way and save many patients.

The Bayer Cares Foundation has nominated the project for the 2017 Aspirin Social Innovation Award and will present it, along with other groundbreaking ideas, as part of 'The Beauty of Impact' panel at the World Health Summit 2017. The Bayer foundations' lineup will include the social entrepreneur and founder of Discovering Hands, Dr. Frank Hoffmann, who is training blind women to perform breast examinations, as well as Martin Aufmuth, the founder of OneDollarGlasses, a charitable company that produces spectacles for one dollar, with the goal of enabling everyone all over the world to purchase spectacles when needed.

The entire World Health Summit is open to the media: www.worldhealthsummit.org/media/accreditation

Find more information at: www.bayer-foundations.com

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG published this content on 13 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 October 2017 08:04:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
04:01pBAYER : Next generation of agricultural talent invited to 'plant their path' at ..
01:00pMONSANTO INDIA : appoints Cherukuri Ravishankar as new MD
09/24BAYER : Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Co..
09/22BAYER : Receives Positive CHMP Opinion for Its Hemophilia a Treatment BAY94-9027
09/22BAYER : Jivi Approved in Japan for Hemophilia a
09/21BAYER : collaborates with One Acre Fund to support smallholders in Africa with a..
09/20BAYER : "Fungicidal Compositions And Methods" in Patent Application Approval Pro..
09/20MONSANTO : Patent Issued for Plants And Seeds Of Hybrid Corn Variety CH624975 (U..
09/20BAYER : Compugen earns $7.8m payment from Bayer
09/20MONSANTO : Patent Application Titled "Containerized Liquid Formulations" Publish..
More news
News from SeekingAlpha
09/24DowDuPont And Bayer, Post-Merger Opportunities? 
09/21Feds looking into free services from drug makers - WSJ 
09/21Bayer's Jivi OK'd in Japan for hemophilia A 
09/20Compugen receives milestone payment in cancer immunotherapy collaboration wit.. 
09/19Bayer steps up legal fight over weedkiller, asks court to toss $289M jury awa.. 
Financials (€)
Sales 2018 39 131 M
EBIT 2018 7 240 M
Net income 2018 4 971 M
Debt 2018 39 542 M
Yield 2018 3,72%
P/E ratio 2018 15,00
P/E ratio 2019 14,06
EV / Sales 2018 2,83x
EV / Sales 2019 2,28x
Capitalization 71 014 M
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 102 €
Spread / Average Target 34%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-25.23%83 392
JOHNSON & JOHNSON2.26%376 847
PFIZER21.29%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY26.36%188 241